Targeted Therapy for ER Positive Breast Cancer: 68 Real Stories

68 stories match breast cancer, ER positive and targeted therapy. 56 of them mention surgery.

Cancer Stories

A patient, who was diagnosed with Stage IV Breast CancerBreast Cancer

Metastatic Breast Cancer Treatment Complicated by a Supplement–Drug Interaction

Patient Info: Anonymized, female, 50s | Stage IV

Biomarkers: ER-positive, PR-positive, HER2-negative

Metastatic Site: bones

She resumed ribociclib with letrozole after the supplement was discontinued and the treatment-related neutropenia improved enough to restart therapy.

PubMed Central
OutcomeCare Ongoing
Abigail, who was diagnosed with Stage IV Breast CancerBreast Cancer

Stage IV HR-Positive Breast Cancer: Abigail's Patient Story

Patient Info: Abigail Myers, female, Under 40 | Stage IV

Biomarkers: ER-positive, PR-positive, HER2-positive

Metastatic Site: bones, brain

Abigail continued living with Stage IV metastatic breast cancer after about 8 years of multiple treatment lines, including therapy for bone and brain metastases.

Dana-Farber
OutcomeLiving With Cancer
A patient, who was diagnosed with Stage IV Invasive Ductal CarcinomaBreast Cancer

Chemotherapy complication: methotrexate absorbed into the bloodstream after spinal injection

Patient Info: Anonymized, Female | Stage IV

Biomarkers: ER-positive; PR-positive; HER2-negative; Oncotype DX Recurrence Score 20

Metastatic Site: leptomeninges / central nervous system; brain

Five months after leptomeningeal carcinomatosis was recognised, she developed a new 2 cm brain lesion and neurological decline. Her family chose supportive care, and she died 10 days after transfer to inpatient hospice.

PubMed Central
OutcomeIn Memory
A patient, who was diagnosed with Stage IV Invasive Lobular CarcinomaBreast Cancer

Breast cancer that spread to the thymus gland

Patient Info: Anonymized, Female | Stage IV

Biomarkers: Oestrogen receptor-positive; progesterone receptor-positive; HER2-negative

Metastatic Site: thymus

She had a good response after 4 cycles of abemaciclib, anastrozole and goserelin and continued endocrine treatment with surveillance of the opposite breast.

PubMed Central
OutcomeResponding Well
A patient, who was diagnosed with Stage IV Invasive Ductal CarcinomaBreast Cancer

Metastatic Breast Cancer Reclassified After NTRK Fusion Testing

Patient Info: Anonymized, Female | Stage IV

Biomarkers: ETV6-NTRK3 fusion detected in tissue but not circulating tumor DNA; ER low-positive; PR-negative; HER2-negative; PD-L1-negative; germline CHEK2 variant of uncertain significance

Metastatic Site: lungs and pleura; hilar, mediastinal and retrocaval…

After tissue testing identified an ETV6-NTRK3 fusion, treatment with larotrectinib produced a rapid clinical and radiological response.

PubMed Central
OutcomeResponding Well
A patient, who was diagnosed with Stage IV Invasive Ductal CarcinomaBreast Cancer

A durable response to trastuzumab in heavily pretreated metastatic breast cancer

Patient Info: Anonymized, Female, 60s | Stage IV

Biomarkers: Initial tumor ER-positive and PR-positive. Metastatic liver biopsy ER-negative and PR-negative with HER2 IHC 1+ and nonamplified. Later biopsy ER and PR weakly positive at 5%–10%, HER2 IHC 1+ and nonamplified, and ERBB3 p. with evidence of HER2/HER3 pathway activation.

Metastatic Site: lungs; hilar and mediastinal lymph nodes; liver; bone

She had ongoing benefit for more than 10 months on trastuzumab and capecitabine, with improved symptoms, lower tumor markers, and a confirmed partial response.

PubMed Central
OutcomeResponding Well
Faith, who was diagnosed with Stage II Breast CancerBreast Cancer

Stage II HR-Positive Breast Cancer: Faith's Survivor Story

Patient Info: Faith, Female, Under 40 | Stage II

Biomarkers: ER-positive; HER2-positive

Faith moved into survivorship after treatment for Stage II ER-positive, HER2-positive breast cancer, with ongoing fear of recurrence but renewed focus on family, nutrition, exercise, and work.

Our Cancer Stories
OutcomeSurvivorship / Completed Treatment
A patient, who was diagnosed with Stage IV Invasive Lobular CarcinomaBreast Cancer

Occult lobular breast cancer first discovered through colon metastases

Patient Info: Anonymized, Female, 70+ | Stage IV

Biomarkers: ER-positive; PR-negative; HER2-negative; E-cadherin-negative

Metastatic Site: colon

Her tumour marker decreased during letrozole and palbociclib treatment, but recurrent infections interrupted therapy, and she died from urosepsis 2 years after diagnosis.

PubMed Central
OutcomeIn Memory
A patient, who was diagnosed with Stage IV Invasive Ductal CarcinomaBreast Cancer

HER2-positive breast cancer diagnosed during pregnancy and later spread to bone and brain

Patient Info: Anonymized, Female, Under 40 | Stage IV

Biomarkers: Initial tumour: ER 0%, PR <1%, HER2 3+

Metastatic Site: bone (L3)|brain

After treatment and surveillance without new lesions, she developed a large symptomatic occipital brain metastasis 14 months after completing paclitaxel and radiation and died after rapid neurological deterioration.

PubMed Central
OutcomeIn Memory
A patient, who was diagnosed with Invasive Ductal CarcinomaBreast Cancer

Heart Failure and Electrical Conduction Changes During Trastuzumab Treatment

Patient Info: Anonymized, Female, 70+

Biomarkers: HER2-positive; ER-positive

Trastuzumab was suspended after acute heart failure and electrical conduction abnormalities; 4 weeks later, left ventricular function recovered and the ECG returned to normal during cardio-oncology follow-up.

PubMed Central
OutcomeNot reported
A patient, who was diagnosed with Invasive Ductal CarcinomaBreast Cancer

Fatal Bowel Infection After the First Chemotherapy Cycle for Early HER2-Positive Breast Cancer

Patient Info: Anonymized, Female, 70+

Biomarkers: ER-positive; PR-positive; HER2-amplified

Nine days after the first TCH cycle, she developed fulminant febrile neutropenia and Clostridium septicum sepsis with extensive bowel ischaemia; despite emergency treatment and resuscitation, she died 4 hours after hospital arrival.

PubMed Central
OutcomeIn Memory
Kirby, who was diagnosed with Stage IV Breast CancerBreast Cancer

Stage IV Breast Cancer: Kirby's Patient Story

Patient Info: Kirby Lewis, Male | Stage IV

Biomarkers: ER-positive, PR-positive, HER2-negative

Metastatic Site: lung|spine

Kirby was living with metastatic breast cancer, and his most recent scans showed the right-lung tumor was stable with no signs of progression while he continued fulvestrant and palbociclib.

AACR
OutcomeStable Disease
A patient, who was diagnosed with Stage IV Invasive Ductal CarcinomaBreast Cancer

Breast Cancer Recurrence in the Parotid Gland Eight Years Later

Patient Info: Anonymized, Female, 50s | Stage IV

Biomarkers: Primary breast tumor: ER-positive and HER2-positive. Parotid metastasis: ER-positive, PR-negative, and HER2-positive.

Metastatic Site: left parotid gland

The isolated parotid metastasis was completely resected, one-month PET-CT showed no significant abnormality, and endocrine therapy continued with exemestane.

PubMed Central
OutcomeCare Ongoing
MB
Breast Cancer

Metastatic Breast Cancer Presenting With Severe Pulmonary Hypertension

Patient Info: Anonymized, Female, Under 40 | Stage IV

Biomarkers: ER-positive; PR-positive.

Metastatic Site: bone; bone marrow

At seven months, she was doing well with a marked response on PET imaging, normalized right-heart pressures, and ongoing systemic treatment with palbociclib.

PubMed Central
OutcomeResponding Well
A patient, who was diagnosed with Stage IV Invasive Ductal CarcinomaBreast Cancer

Breast cancer recurrence involving the bladder and bones

Patient Info: Anonymized, Female | Stage IV

Biomarkers: Initial breast cancer: ER-positive, PR-positive, HER2-negative. Bladder metastasis: ER-positive, PR-negative, HER2 1+.

Metastatic Site: bladder, bone, rectosigmoid region, anorectal region

She died in October 2016 from pulmonary haemorrhage, 47 months after metastatic disease was diagnosed.

PubMed Central
OutcomeIn Memory
A patient, who was diagnosed with Stage III Breast CancerBreast Cancer

Triple receptor-positive neuroendocrine breast cancer in a 32-year-old woman

Patient Info: Anonymized, Female, Under 40 | Stage III

Biomarkers: ER positive; PR positive; HER2 positive; neuron-specific enolase positive; synaptophysin positive

She was stable on follow-up and was receiving adjuvant chest-wall radiation plus systemic chemotherapy and trastuzumab-based therapy.

PubMed Central
OutcomeCare Ongoing